LINTAZ 4.5 Injection/Powder for

What is LINTAZ 4.5

LINTAZ 4.5 is a broad-spectrum antibiotic injection that contains two active ingredients: Piperacillin, a ureidopenicillin-type beta-lactam antibiotic, and Tazobactam, a beta-lactamase inhibitor. The combination is formulated as a powder that must be reconstituted with a compatible solvent before intravenous administration. It is designed to combat a wide range of serious bacterial infections, particularly those caused by resistant Gram-negative and Gram-positive organisms.

LINTAZ is commonly used in the hospital setting to manage:

• Intra-abdominal infections (e.g., peritonitis, appendicitis)
• Complicated skin and soft tissue infections
• Nosocomial pneumonia, including ventilator-associated pneumonia
• Urinary tract infections and pyelonephritis
• Bacteremia and sepsis

It is typically reserved for moderate to severe infections or when standard antibiotics have failed or are unsuitable due to resistance patterns.

How to use LINTAZ 4.5

LINTAZ 4.5 is administered by healthcare professionals only and is not for self-administration.

• Each vial contains Piperacillin 4 g + Tazobactam 0.5 g
• The powder must be reconstituted with sterile water for injection or another compatible diluent
• Administered as a slow intravenous infusion over 20–30 minutes
• Dosing intervals are typically every 6 to 8 hours depending on infection severity and renal function

Dosing must be adjusted in patients with impaired renal function or those undergoing dialysis. Duration of treatment depends on clinical response and the site of infection.

Mode of Action LINTAZ 4.5

LINTAZ 4.5 combines the bactericidal action of Piperacillin with the beta-lactamase inhibiting activity of Tazobactam:

• Piperacillin: Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis
• Tazobactam: Inhibits beta-lactamases, enzymes produced by bacteria to resist beta-lactam antibiotics

Together, the combination expands antibacterial coverage and is effective against organisms that produce beta-lactamase enzymes, making it a robust option for treating multidrug-resistant infections.

LINTAZ 4.5 Interactions LINTAZ 4.5

Several drug interactions should be considered during LINTAZ therapy:

• Anticoagulants (e.g., warfarin): Increased risk of bleeding due to platelet inhibition
• Aminoglycosides: Inactivation may occur when mixed in the same IV solution; administer separately
• Vecuronium: Enhanced neuromuscular blockade may occur
• Methotrexate: Prolonged elimination; monitor for toxicity
• Probenecid: Inhibits renal excretion of both components, raising blood levels

Patients should inform healthcare providers of all medications they are taking before beginning therapy.

Dosage of LINTAZ 4.5

Typical dosing for adults:

• Standard Dose: 4.5 g every 8 hours via IV infusion
• Severe Infections: May require more frequent dosing (e.g., every 6 hours)
• Renal Impairment: Dose adjustments required according to creatinine clearance levels
• Pediatric Use: Weight-based dosing; consult specialist guidance

Duration usually ranges from 7 to 14 days but may be extended for complex infections. Treatment should continue for at least 48–72 hours after symptom resolution.

Possible side effects of LINTAZ 4.5

Possible Side Effects of LINTAZ 4.5

Like all medications, LINTAZ can cause side effects, some of which may be serious:

• Common: Diarrhea, rash, nausea, and injection site reactions
• Hematologic: Leukopenia, thrombocytopenia, anemia with prolonged use
• Renal: Elevated creatinine or renal impairment (especially with other nephrotoxic drugs)
• Hepatic: Mild elevations in liver enzymes (AST, ALT)
• Allergic Reactions: Anaphylaxis, especially in penicillin-allergic patients

Prompt medical attention is required if signs of hypersensitivity, bleeding, or severe diarrhea (e.g., C. difficile colitis) occur.

LINTAZ 4.5 Contraindications LINTAZ 4.5

• Known hypersensitivity to Piperacillin, Tazobactam, or other beta-lactam antibiotics
• Severe allergic reaction (e.g., anaphylaxis) to penicillins, cephalosporins, or carbapenems
• History of antibiotic-associated colitis (use with caution)

Caution is also warranted in patients with renal impairment or hematologic disorders.

Storage of LINTAZ 4.5

• Store vials below 25°C (77°F), in a dry place
• Protect from excessive moisture and heat
• After reconstitution, use immediately or as per hospital protocol (usually within 24 hours if refrigerated)
• Keep out of the reach of children

Discard any unused solution safely following proper medical waste guidelines.